Botulinum neurotoxin type A subtype 2 confers greater safety than subtype in a rat Parkinson’s disease model

Masanori Itakura; Tomoko Kohda; Takeya Kubo; Yuko Semi; Kazuhiro Nishiyama; Yasu Taka Azuma; Hidemitsu Nakajima; Shunji Kozaki; Tadayoshi Takeuchi

doi:10.1292/jvms.14-0184

Botulinum neurotoxin type A subtype 2 confers greater safety than subtype in a rat Parkinson’s disease model

Masanori Itakura, Tomoko Kohda, Takeya Kubo, Yuko Semi, Kazuhiro Nishiyama, Yasu Taka Azuma, Hidemitsu Nakajima, Shunji Kozaki, Tadayoshi Takeuchi

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Botulinum neurotoxin type A (BoNT/A) cleaves SNAP-25 and interrupts the release of acetylcholine. We previously reported that BoNT/A subtype 2 (BoNT/A2) ameliorates pathologic behavior more effectively than subtype 1 (BoNT/A1) in a rat Parkinson’s disease model. Here, we further show BoNT/A2 has fewer adverse effects than BoNT/A1. We first confirmed that intrastriatal treatments of both BoNT/As had no-effect on dopaminergic terminals in the striatum. SNAP-25 cleaved by BoNT/A2 was strictly localized to the striatum on the injected side; however, SNAP-25 cleaved by BoNT/A1 diffused contralaterally. Furthermore, treatment with BoNT/A1 caused a significant reduction in body weight, while BoNT/A2 treatment did not. These results suggest that BoNT/A2 is more beneficial for clinical application against Parkinson’s disease than BoNT/A1.

Original language	English
Pages (from-to)	1189-1193
Number of pages	5
Journal	Journal of Veterinary Medical Science
Volume	76
Issue number	8
DOIs	https://doi.org/10.1292/jvms.14-0184
Publication status	Published - 2014
Externally published	Yes

All Science Journal Classification (ASJC) codes

veterinary(all)

Access to Document

10.1292/jvms.14-0184

Cite this

@article{e890e06e2eb843e8a12ce2e6c255f48a,

title = "Botulinum neurotoxin type A subtype 2 confers greater safety than subtype in a rat Parkinson{\textquoteright}s disease model",

abstract = "Botulinum neurotoxin type A (BoNT/A) cleaves SNAP-25 and interrupts the release of acetylcholine. We previously reported that BoNT/A subtype 2 (BoNT/A2) ameliorates pathologic behavior more effectively than subtype 1 (BoNT/A1) in a rat Parkinson{\textquoteright}s disease model. Here, we further show BoNT/A2 has fewer adverse effects than BoNT/A1. We first confirmed that intrastriatal treatments of both BoNT/As had no-effect on dopaminergic terminals in the striatum. SNAP-25 cleaved by BoNT/A2 was strictly localized to the striatum on the injected side; however, SNAP-25 cleaved by BoNT/A1 diffused contralaterally. Furthermore, treatment with BoNT/A1 caused a significant reduction in body weight, while BoNT/A2 treatment did not. These results suggest that BoNT/A2 is more beneficial for clinical application against Parkinson{\textquoteright}s disease than BoNT/A1.",

author = "Masanori Itakura and Tomoko Kohda and Takeya Kubo and Yuko Semi and Kazuhiro Nishiyama and Azuma, {Yasu Taka} and Hidemitsu Nakajima and Shunji Kozaki and Tadayoshi Takeuchi",

year = "2014",

doi = "10.1292/jvms.14-0184",

language = "English",

volume = "76",

pages = "1189--1193",

journal = "Journal of Veterinary Medical Science",

issn = "0916-7250",

publisher = "Japanese Society of Veterinary Science",

number = "8",

}

TY - JOUR

T1 - Botulinum neurotoxin type A subtype 2 confers greater safety than subtype in a rat Parkinson’s disease model

AU - Itakura, Masanori

AU - Kohda, Tomoko

AU - Kubo, Takeya

AU - Semi, Yuko

AU - Nishiyama, Kazuhiro

AU - Azuma, Yasu Taka

AU - Nakajima, Hidemitsu

AU - Kozaki, Shunji

AU - Takeuchi, Tadayoshi

PY - 2014

Y1 - 2014

N2 - Botulinum neurotoxin type A (BoNT/A) cleaves SNAP-25 and interrupts the release of acetylcholine. We previously reported that BoNT/A subtype 2 (BoNT/A2) ameliorates pathologic behavior more effectively than subtype 1 (BoNT/A1) in a rat Parkinson’s disease model. Here, we further show BoNT/A2 has fewer adverse effects than BoNT/A1. We first confirmed that intrastriatal treatments of both BoNT/As had no-effect on dopaminergic terminals in the striatum. SNAP-25 cleaved by BoNT/A2 was strictly localized to the striatum on the injected side; however, SNAP-25 cleaved by BoNT/A1 diffused contralaterally. Furthermore, treatment with BoNT/A1 caused a significant reduction in body weight, while BoNT/A2 treatment did not. These results suggest that BoNT/A2 is more beneficial for clinical application against Parkinson’s disease than BoNT/A1.

AB - Botulinum neurotoxin type A (BoNT/A) cleaves SNAP-25 and interrupts the release of acetylcholine. We previously reported that BoNT/A subtype 2 (BoNT/A2) ameliorates pathologic behavior more effectively than subtype 1 (BoNT/A1) in a rat Parkinson’s disease model. Here, we further show BoNT/A2 has fewer adverse effects than BoNT/A1. We first confirmed that intrastriatal treatments of both BoNT/As had no-effect on dopaminergic terminals in the striatum. SNAP-25 cleaved by BoNT/A2 was strictly localized to the striatum on the injected side; however, SNAP-25 cleaved by BoNT/A1 diffused contralaterally. Furthermore, treatment with BoNT/A1 caused a significant reduction in body weight, while BoNT/A2 treatment did not. These results suggest that BoNT/A2 is more beneficial for clinical application against Parkinson’s disease than BoNT/A1.

UR - http://www.scopus.com/inward/record.url?scp=84906871918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906871918&partnerID=8YFLogxK

U2 - 10.1292/jvms.14-0184

DO - 10.1292/jvms.14-0184

M3 - Article

C2 - 24849052

AN - SCOPUS:84906871918

SN - 0916-7250

VL - 76

SP - 1189

EP - 1193

JO - Journal of Veterinary Medical Science

JF - Journal of Veterinary Medical Science

IS - 8

ER -

Botulinum neurotoxin type A subtype 2 confers greater safety than subtype in a rat Parkinson’s disease model

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this